Close Menu

Oxford Nanopore

Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments — MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.

Oxford Nanopore Facts

 

CEO: Gordon Sanghera

Website: www.nanoporetech.com

Ticker symbol: Privately held

Headquarters: Oxford, UK

Number of employees: 250+

Researchers funded in part by Oxford Nanopore recently published a study showing nanopores can detect proteins at the single-molecule level.

The company plans to use the new funding to expand into Asia, with a particular focus on China.

The researchers said that although improvements are needed for accurate basecalling, the MinIon is suitable for structural variant identification and haplotype phasing. 

The assembly of the agricultural pest Rhizoctonia solani genome was more contiguous and larger than previous short-read assemblies.

During a live webcast, CTO Clive Brown provided an update on the company's development plans and upcoming updates.

The next step to sequencing organisms found on the ISS or in space is to automate sample and library prep, according to a NASA microbiologist.

Researchers have shown that metagenomic sequencing on the MinIon can identify the pathogen and antimicrobial resistance profile of UTIs in several hours. 

The researchers demonstrated their Nanocall software on both E. coli and human DNA samples, showing it is comparable to an older version of the cloud-based software.

Under the terms of the settlement, Illumina and co-plaintiffs can request up to five audits of Oxford Nanopore's products.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.